📢 Join leading oncologist Dr Dana Chase as she explores the role of HER2 as a pan tumour biomarker and its implications for treatment planning across different cancer types.
Discover how HER2-tumour agnostic therapies are reshaping cancer care.
🎥 Watch now: touchoncologyi...
Or
Register to stay informed: touchoncology....
This activity is funded by an independent medical education grant from AstraZeneca.
This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.
#MedEd
#BreastCancer
#Gastrointestinal
#Colorectal
#LungCancer
#HER2
#CancerTreatment
#Biomarkers
Негізгі бет touchFOCUS Expanding the reach of HER2 in solid tumours: A spotlight on tumour-agnostic approaches
Пікірлер